Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma Peritonei of Appendiceal Origin by Esquivel, Jesus & Averbach, Andrew
Hindawi Publishing Corporation
Gastroenterology Research and Practice
Volume 2012, Article ID 981245, 5 pages
doi:10.1155/2012/981245
Clinical Study
Laparoscopic Cytoreductive Surgery and HIPEC in Patients with
LimitedPseudomyxoma Peritonei of AppendicealOrigin
Jesus Esquiveland Andrew Averbach
Department of Surgical Oncology, St. Agnes Hospital, Baltimore, MD 21229, USA
Correspondence should be addressed to Jesus Esquivel, jesusesquivel@yahoo.com
Received 12 January 2012; Accepted 16 February 2012
Academic Editor: Pompiliu Piso
Copyright © 2012 J. Esquivel and A. Averbach. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Introduction. Increasing numbers of patients with pseudomyxoma peritonei (PMP) of appendiceal origin are being evaluated with
a low tumor burden. We explored a minimally invasive approach for this group of patients. Materials and Methods. We designed
a protocol in which patients with a PMP diagnosis would have a diagnostic laparoscopy. If limited carcinomatosis (PCI≤10) is
identiﬁed, the procedure will continue laparoscopically. If extensive carcinomatosis (PCI>10) is found, then the procedure will be
c o n v e r t e dt oa no p e na p p r o a c h .Results. From December 2008 to December 2011, 19 patients had a complete cytoreduction and
HIPEC: 18 of them (95%) were done laparoscopically and 1 of them (5%) was converted to an open procedure. Mean PCI was 4.2.
Grade 3 morbidity was 0, and one patient (5%) experienced a grade 4 complication, needing a reoperation for an internal hernia.
There were no mortalities. Mean length of hospital stay was 5.3 days. At a mean follow-up of 17 months (1–37) all 19 patients are
alive and free of disease. Conclusion. This study demonstrates that cytoreductive surgery and HIPEC via the laparoscopic route is
feasible and safe and should be oﬀered to patients with limited pseudomyxoma peritonei of appendiceal origin.
1.Introduction
Cytoreductive surgery (CRS) and hyperthermic intraperi-
tonealchemotherapy(HIPEC)havebecomestandardofpra-
cticeinpatientswithpseudomyxomaperitonei[1].Theopen
procedure has been associated with grade III and IV mor-
bidity and prolonged hospitalization. In addition, many pa-
tientswithPMParebeingreferredtoaperitonealsurfacema-
lignancy center as soon as they are diagnosed and not after
3 or 4 abdominal procedures as we used to see in the late
90s. Furthermore, the number of patients that are diagnosed
afteralaparoscopicappendectomyisontheriseaswell.What
to do in this particular group of patients is still a matter of
debate, with half of the cytoreductive surgeons recommend-
ing a watch-and-wait approach and the other half recom-
mendingcytoreductivesurgeryandHIPEC.Oneoftheprob-
lems with the watch-and-wait approach is that it generates
anxiety in some patients and that the followup requires
numerous CT scans. This of course exposes the patient to
increasing doses of radiation. MRI is becoming a very use-
ful tool to evaluate the abdomen and pelvis for additional
mucinous implants and hopefully will help to reduce the
amount of radiation exposure. An obvious disadvantage of
treating every patient with PMP with a very large incision
in order to rule out the presence of any residual disease is the
factthatmanyofthesepatientsaregoingtohaveverylimited
peritoneal disease. Therefore, this approach represents an
opportunity to improve patient care. In this modern era of
individualized medicine, reports on laparoscopic surgery for
cancerpatientshavebeenpublishedinjustabouteveryorgan
in the abdomen [2–4]. Prospective randomized trials have
shown that there is no diﬀerence in port site and wound
recurrence,nodiﬀerenceindistantrecurrence,andnodiﬀer-
ence in survival in patients undergoing laparoscopic surgery
for primary colon cancer, in fact, some of these studies show
a better outcome in those having laparoscopic surgery [5].
For these reasons, and understanding that laparoscopic
surgery is not ad i ﬀe r e n ts u r g e r yb u tr a t h e rj u s tad i ﬀerent
approach, our group decided to evaluate the role of laparo-
scopic cytoreductive surgery and HIPEC in patients with
limited peritoneal dissemination. The results with the ﬁrst
14 patients that included a variety of peritoneal surface2 Gastroenterology Research and Practice
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Figure 1: Clinical pathway for the laparoscopic management of
peritoneal surface malignancies.
malignancies look very promising and have been previously
published [6]. The purpose of this paper is to report our
continued experience from this protocol in patients with
pseudomyxomaperitoneiofappendicealorigin,alsoreferred
to as low-grade mucinous carcinoma peritonei (L-MCP) or
disseminated peritoneal adenomucinosis (DPAM).
2.MaterialsandMethods
Patientswithahistologicaldiagnosisoflow-grade,mucinous
carcinoma peritonei of appendiceal origin and no gross
evidence of carcinomatosis on the CT scan were subjected to
a diagnostic laparoscopy to determine the peritoneal cancer
index. During laparoscopy, if low-volume carcinomatosis is
identiﬁed, deﬁned as a Peritoneal Cancer Index (PCI) ≤ 10,
theoncologicalprocedurewillbecontinuedlaparoscopically.
If at the time of the diagnostic laparoscopy high-volume
carcinomatosis is identiﬁed, deﬁned as a PCI > 10, the pro-
cedure will be converted to the standard open approach. The
protocol (RPN 2008-020) was approved by our Institutional
Review Board (Figure 1).
The operative team consisted of a very experienced
laparoscopic surgeon (A. Averbach) who normally performs
more than 150 complex laparoscopic bariatric operations a
year and a cytoreductive surgeon (J. Esquivel). The proce-
dures were performed in an integrated minimally invasive
operating room with STORZ high-deﬁnition laparoscopic
equipment. The peritoneal cavity was accessed in the right-
upper quadrant with a direct view 12mm Visiport with
a 0 degree laparoscope. Once the pneumoperitoneum was
established, two additional 12mm trocars were placed in the
periumbilical and left-upper quadrants under direct visuali-
zation. Two 5mm trocars were placed below the right and
left costal margins. Occasionally, a sixth trocar (5mm) was
placed in the midline above the symphysis pubis to facilitate
Figure 2: Laparoscopic hyperthermic intraperitoneal chemother-
apy (HIPEC).
upper abdomen dissections. Lysis of adhesions was per-
formed to free all intra-abdominal structures, and a detailed
exploration of both parietal and visceral peritoneum was
carried out in order to determine the laparoscopic Peritoneal
Cancer Index (PCI). This was facilitated by instrument
retraction and positioning the operating room table for
gravity-assisted retraction in order to maximize exposure
of dependent areas. Once the diagnostic laparoscopy was
completed, a decision to continue with the cytoreduction via
the laparoscopic route was made based on two factors: the
PCI had to be 10 or less and the amount of disease present
had to be able to be removed laparoscopically according to
the senior surgeon (A. Averbach). We decided on a PCI of 10
or less as this amount of carcinomatosis is what we normally
consider as low-volume carcinomatosis in all peritoneal
surfacemalignancies.Allpatientsunderwentagreateromen-
tectomyeveniftherewasnoevidenceofmacroscopicdisease.
Thegreateromentumwasmobilizedoﬀthetransversecolon,
anditshepaticandsplenicﬂexuresweretakendownforcom-
pleteexcisionusingtheHarmonicscalpel(EthiconInc.,Gua-
ynabo, PR). The gastrosplenic ligament was severed close to
thesplenichilum.Additionalvisceralresectionsandperiton-
eal stripping were performed as needed in order to achieve
a complete cytoreduction. Bowel resections were performed
with an Endo GIA 3.5/60mm cartridge (US Surgical,
Norwalk, CT) and the staple lines inverted with a running
2.0 Surgidac Endostitch (US Surgical, Norwalk, CT) when
needed.ThebowelmesenterywastransectedwiththeHarm-
onicscalpel(EthiconInc.,Guaynabo,PR).Bilateralsalpingo-
oophorectomies were done with suture ligation of the
origins of the Fallopian tubes and subsequent dissection
with the Harmonic scalpel (Ethicon Inc., Guaynabo, PR).
At the end of the laparoscopic stage of the procedure,
a 6cm periumbilical midline laparotomy was performed
and the specimens were extracted. Two inﬂow and 2 out-
ﬂow perfusion catheters were placed, and the skin at the
laparotomy and port sites was closed with a running nylon
stitch to avoid chemotherapy solution leakage and to ex-
pose all incisions to its action to reduce the risk of tumor cell
implantation. Hyperthermic intraperitoneal chemotherapy
with 40mg of Mitomycin C for 90 minutes at 43 degrees
Celsius was administered using either the Belmont (Belmont
Instruments, Billerica, MA) or ThermaSolutions (Therma-
solutions Inc., Pittsburgh, PA) perfusion systems (Figure 2).Gastroenterology Research and Practice 3
Table 1: Mode of presentation in 18 patients with PMP.
Event Number Percentage
Ovarian mass 6 33
Abdominal Pain/CT scan 6 33
Appendicitis 3 16
Other 3 16
At the completion of the heated perfusion, gastrointestinal
anastomosis was performed as indicated, the midline lapar-
otomy incision was closed with a running looped 1.0 Maxon
stitch (US Surgical, Norwalk, CT), the trocars were reinser-
ted, and the peritoneal cavity was explored to assure lack of
visceral injuries and/or bleeding sources. The 12mm port
site incisions were closed with 0 POLYSORB (US Surgical,
Norwalk,CT)withaCarter-Thomasonsutureclosingsystem
(Cooper Surgical, Trumbull, CT). In the patient in whom
the procedure was converted to an open intervention,
the same principles were followed: resections were made,
the chemotherapeutic perfusion was carried via the closed
abdomen method, and after the perfusion the abdomen was
closed with a running looped 1.0 Maxon stitch (US Surgical,
Norwalk, CT). Postoperative complications were reported
according to the National Cancer Institute Common Toxicity
Criteria. Follow-up included a CEA and CA 19-9 every 3
months, a baseline postoperative CT scan at 4 months and
then a repeat CT scan or MRI every 6 months.
3. Results
From December 2008 to December 2011, 30 patients with
limited peritoneal surfacemalignancies were taken to the op-
erating room for a laparoscopic cytoreductive surgery and
HIPEC. Of these 30 patients, 19 patients had the diagnosis
of Pseudomyxoma Peritonei of appendiceal origin and cons-
titute the basis of this study. The most common form of
presentation of their appendiceal mucinous neoplasm was
an ovarian mass with nearly half of the female patients, 6
out of 14 presenting this way (Table 1). Thirteen patients
were enrolled into the protocol with 8 of them previously
reported in another manuscript [6]. Once the protocol was
completed, we included 6 more patients done oﬀ-protocol.
There were 15 females and 4 male patients. Mean age was
52 (38–74). All patients had previous surgeries. Sixty-six
percent had a previous laparoscopic procedure and 33% a
previous open procedure. Median time from initial surgery
to cytoreduction and HIPEC was 3 months (1–22). All 19
patients had a complete cytoreduction and HIPEC; 18 (95%)
were done laparoscopically and 1 (5%) was converted to an
open procedure because the evaluation by the senior surgeon
(A. Averbach) indicated that we would not be able to remove
the disease that was present in the previous anastomosis
via the laparoscopic route. This case, which was the third
patient on the study, is the only patient with PMP that was
converted to an open procedure, and it happened 33 months
ago; since then, the following 16 cases have been completed
laparoscopically. The mean PCI was 4.3 (1–10), and mean
Table 2: Characteristics of patients with limited pseudomyxoma
peritonei (L-MCP) treated with cytoreductive surgery and HIPEC.
Variable Laparoscopic
CRS and HIPEC
Laparoscopic to
open CRS and
HIPEC
Number of patients (n)1 8 1
Mean age 50 74
Sex
Male 4 0
Female 14 1
Previous surgery
No 0 0
Yes 18 1
Previous chemotherapy
No 18 1
Mean body mass index 26.2 29.1
Mean peritoneal cancer index 4.2 10
Complete cytoreduction
Yes 18 1
Bowel resection
No 13 1
Yes 5 0
Mean estimated blood loss 50mL 100mL
Mean blood transfused 0 0
Mean duration of surgery 4.2 hours 5 hours
Grade 3 complications
No 18 1
Grade 4 complications
No 17 1
Yes 1 0
Mean length of hospital stay 5.3 days 7 days
M e a nf o l l o w - u p 1 7m o n t h s 3 3m o n t h s
Table 3: Procedures performed in 18 patients undergoing laparo-
scopic cytoreduction.
Surgical resection Number Percentage
Greater omentectomy 17 94
Limited peritonectomy 8 44
Bowel resection 5 27
Salpingo-oophorectomy 2 11
operative time was 4.2 hours (3.5–6) (Table 2). Forty-
four percent of the patients required a limited peritone-
ctomy, and 27% required a bowel resection (Table 3). Mean
bloodlosswas50mL,andnopatientsreceivedabloodtrans-
fusion. All patients were extubated at the end of the proce-
dure and transferred to the postanesthesia care unit and then
to the regular surgical ward. No nasogastric tubes or intra-
abdominal drains were placed. Grade 3 morbidity was zero,
and one patient (5%) in the laparoscopy group experienced
a grade 4 complication, needing a reoperation for an internal
hernia; this reoperation was also completed laparoscopically,4 Gastroenterology Research and Practice
Table 4: Summary of pathological ﬁndings.
Event Number Percentage
Extracellular mucinous deposits
outside of the appendix 18 100
Epithelial cells present
outside of the appendix 13 72
Omentum with grossly
normal appearance 16 89
Final pathology positive 13 81
Pathology of the omentum
showing extracellular mucin 10 62
Pathology of the omentum
showing epithelial cells 31 8
and the patient went home 14 days after the ﬁrst surgery.
There were no operative deaths. Mean length of hospital stay
was 5.3 days (3–14). A summary of pathological ﬁndings is
included on Table 4. At a mean followup of 17 months (1–
37),allpatientsarealiveandwell,withnoevidenceofdisease
recurrence.
4. Discussion
T h eﬁ r s tc a s er e p o rto fc yt o r e d u ct i v es u r g e rya n dH I P E Ci na
patient with Pseudomyxoma Peritonei (PMP) of appendiceal
origin dates back to 1979 [7]. Since then, cytoreductive sur-
gery and HIPEC have become the standard treatment for
this group of patients even though there has never been a
prospective randomized trial. Analysis of the published data
demonstrates that a complete surgical eradication of this
low-grade type of tumor is associated with the best out-
come,andwhiletheaddedbeneﬁtofthehyperthermicintra-
peritoneal chemotherapy to a complete cytoreduction con-
tinues to be a matter of debate and has never been clearly
established, a trial that would compare cytoreductive surgery
with or without HIPEC in patients with PMP is just not a
feasible trial.
When it comes to the mode of presentation of PMP of
appendicealorigin,nothinghaschangedtoomuchinthelast
3 decades. An ovarian mass continues to be a very common
presentation in women, as well as being diagnosed after an
appendectomy for appendicitis. What has changed is the
amount of tumor burden. An increasing abdominal girth
used to be a very common presentation [8], and now it is
becomingaratherinfrequentone.Thetreatmentremainsthe
same: cytoreductive surgery to remove all visible tumor and
HIPEC to eradicate microscopic residual disease.
Recommending surgery in patients with Pseudomyxoma
peritonei after their initial diagnosis has been established but
now having a negative CT scan on follow-up remains a topic
of discussion. There appears to be an unwritten agreement
on what to do with patients that have no gross evidence of
carcinomatosis but that have epithelial cells outside of the
appendix. Most cytoreductive surgeons will recommend cyt-
oreductive surgery and HIPEC. In this series, 72% of the
patients had epithelial cells outside of the appendix and
extracellular mucin was found in 100% of the patients.
We used to recommend a watch-and-wait followup for
patients that had a perforated appendix, had a negative CT
scan, and only mucin in the periappendiceal tissue. We had
believe that most of these patients will not go on to develop
pseudomyxoma peritonei syndrome. We were concerned
with the amount of radiation exposure as a result of multiple
CT scans,andforthis reasonnow weuseMRItofollowthese
patients. However, some of these patients do not feel com-
fortable with just a watch-and-wait approach, and we do not
believe that a patient should have an exploratory laparotomy
to document that they do not have any disease. This was
the initial rationale for developing a minimally invasive ap-
proach.Itisinterestingthatinthisstudy,ofthe16omentums
that looked normal even during the laparoscopic examina-
tion, 81% had at least mucin found during the pathological
examination. Of course we do not know what would be the
natural history of that ﬁnding, but it is a ﬁnding, that raises
a valid concern.
Our current approach and recommendations are as
follows: if the patient has a ruptured mucinous appendiceal
neoplasm, has a CT scan or MRI with no gross evidence of
peritoneal dissemination, and has epithelial cells in the peri-
appendicealtissue,werecommendalaparoscopiccytoreduc-
tive surgery that includes a greater omentectomy, a portion
of the lesser omentum, a bilateral salpingo-oophorectomy in
postmenopausal women or premenopausal women that do
not wish to have children, and HIPEC. If the patient has a
ruptured mucinous neoplasm with only mucin in the peri-
appendiceal tissue, we recommend a peritoneal metastases
protocol MRI and if that does not show any evidence of
mucinous deposits, then we recommend follow-up with a
routine MRI every 6 months for the ﬁrst 3 years and then
once a year.
It is important to emphasize that this approach needs
longer followup, and as any new therapeutic approach, it
should be done under the auspices of a clinical research pro-
tocol. In order to decrease the learning curve, the surgical
team should include not only a cytoreductive surgeon but a
surgeon that does minimally invasive surgeries on a routine
basis. As mentioned before, our only conversion was 33
months ago this represented our 3rd case, and the patient
that needed the reoperation was our second patient. We
have learned since then that the minimally invasive nature of
early Pseudomyxoma Peritonei is amenable to a minimally
invasive management and treatment.
5. Conclusion
Thisinitialinvestigativestagedemonstratesthatlaparoscopic
cytoreductive surgery and HIPEC in patients with limited
peritoneal dissemination from Pseudomyxoma Peritonei of
appendiceal origin are feasible and safe and therefore should
beaddedtothearmamentariumoftreatmentoptionsforthis
g r o u po fp a t i e n t s .
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